The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase II project is in replacing outdated, hazardous blood bags with a completely non-toxic alternative. Unlike conventional polyvinyl chloride (PVC) bags that contain phthalates—known carcinogens and endocrine disruptors—this new technology eliminates the need for harmful plasticizers and instead uses an FDA-approved, non-chlorinated polymer that keeps blood healthier for longer. Blood transfusions are lifesaving, crucial in surgeries, trauma care, and the treatment of blood disorders, kidney diseases, and neurological conditions. However, the industry faces an urgent challenge: existing blood bags contain up to 40% DEHP plasticizer, which leaches into stored blood. While DEHP helps preserve red blood cells, studies confirm its serious health risks—including links to cancer, asthma, and reproductive toxicity. Regulatory bodies worldwide recognize the danger: California Proposition 65 lists DEHP as a harmful substance, and although the European Union planned to ban DEHP-containing blood bags in 2025, the absence of viable alternatives has delayed enforcement until July 1, 2030. This Small Business Technology Transfer (STTR) Phase II project combines polymer engineering, advanced materials science, and blood biology to create a next-generation composite blood bag that meets stringent medical requirements without leaching harmful substances. The challenge is balancing blood storage effi